Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to improve ...

Private equity house LDC has exited its investment in a North West-based specialised leasing provider of managed re-deployable video surveillance assets for temporary security and ...

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

LDC will exit its investment in Wireless CCTV (WCCTV) to Arcus Infrastructure Partners.

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1/1b ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21, ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

An update from Arcus Development ( ($TSE:ADG.H) ) is now available. Arcus Development Group has completed a 10-for-1 share consolidation, reducing ...

Arcus senilis is when the cornea of your eye has a white or gray ring or arc around it. Your cornea is the transparent outer covering of your eye. It’s also known as corneal arcus. It’s common in ...